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Temple, Tex; and Albany and New York, NY
Objective: To report the 1-year outcomes of the United States (US) regulatory trial of the Endurant Stent Graft System
(Medtronic Vascular), a new device for the treatment of abdominal aortic aneurysms (AAA).
Methods: This was a prospective, single arm, multicenter trial conducted at 26 sites in the US. From April 2008 to May
2009, 150 patients with AAA were treated with the Endurant bifurcated stent graft. The main inclusion criteria were an
AAA diameter >5 cm, proximal neck length >10 mm, bilateral iliac fixation length >15 mm, and a neck angulation of
<60 degrees. A clinical events committee (CEC) adjudicated all adverse events except blood loss, and a core laboratory
reviewed all imaging. The primary safety endpoint was freedom from major adverse events at 30 days, and the primary
effectiveness endpoint was successful aneurysm treatment at 12 months.
Results: One hundred forty-nine patients (99.3%) had a successful stent graft implant, 83.3% under general anesthesia. One
failure was due to inability to cannulate the contralateral gate. One patient developed a neck rupture during the procedure, but
was still treated successfully. Patients were predominantly male (91.3%), elderly (mean age, 73.1 years) with significant
comorbidities. Mean estimated blood loss was 185 mL (range, 0-1450 mL), with blood transfusion required in one patient.
Average hospital stay was 2.1 days. At 1month, themajor adverse events rate was only 4%with no operativemortality. Serious
adverse eventswere recorded in 43of 150 (28.7%) patients. Cardiac (8.7%), fever (6%), urological (4.7%), pulmonary (4%), and
vascular events (4%) were the most frequent. Through 12 months of follow up, there were no migrations, ruptures, or
conversions. No type I or III endoleaks were identified during the first year. Fifteen of 129 patients (11.6%) had endoleaks at
6 months and 13 of 130 (10%) at 1 year, all type II except for one indeterminate endoleak. One Type II endoleak proved to
be a Type IB on later angiography. Ten aneurysm related reinterventions were performed during the first year of follow up,
mostly for limb thrombosis or stenosis (5) or for type II endoleak (2). Four of the procedures were endovascular. Aneurysm
sac diameter decreased>5mm at 1 year in 47% of patients and remained stable in 53%. No sac showed an increase of>5mm.
None of seven late deaths (range, 90-458 days post-implant) was adjudicated to be aneurysm related.
Conclusion: Early results of the Endurant pivotal trial are quite encouraging and suggest a safe and effective new device
for the treatment of abdominal aortic aneurysms. (J Vasc Surg 2011;54:601-8.)
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doi:10.1016/j.jvs.2011.03.002Two endografts were first approved in the United States
US) in September of 1999, ushering the wide dissemination
f endovascular techniques for the treatment of abdominal
ortic aneurysms (AAA).1,2 Rapid adoption of the technology
as been remarkable, resulting in improved acute outcomes of
neurysm treatment nationally.3,4 The early benefits of endo-
ascular aneurysm repair (EVAR) have made it the preferred
pproach for infrarenal AAA management, replacing open
rocedures in the majority of cases across all age ranges.5
natomic limitations to an evenmore expandeduse of EVAR,
owever, remain, and include, among others, inadequate
ccess for large profile devices and iliac aneurysms as well as
oor proximal sealing zones in short or angulated necks.6
ther restraining pressures include mostly the lingering
oubts about long-term outcomes that remain suspect, with a
nite but measurable incidence of ruptures as well as proce-
ure and device-related events requiring reintervention, such as
ndoleaks, migration, disconnections, and structural failures.7,8
Although five devices are currently available commer-
ially, new endograft designs are continuously being tested
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September 2011602 Makaroun et alhoping to improve device performance and short and long
term EVAR results, as well as expand the applicability of
endovascular repair to those with previous anatomic exclu-
sions. Targeted improvements have focused recently on
lower profile carriers, more accurate deployment systems,
active fixation, and more flexibility in dealing with tortu-
ous and challenging anatomy. The Endurant endograft
(Medtronic Vascular, Santa Rosa, CA) combines several of
these desirable characteristics and entered clinical trials in
Europe in 2007. A mandated US regulatory trial started in
2008 and completed enrollment in May of 2009. This
report details the 1-year outcomes of this trial.
METHODS
The device. The Endurant is a modular device made
of multifilament polyester fabric and electropolished Ni-
tinol stents. Proximally, it has a suprarenal fixation system
made of a one- piece laser-cut Nitinol stent with anchoring
pins. The first sealing stent is M-shaped, intended to pro-
vide good neck conformability. The remaining stent struc-
ture of the body and limbs was engineered to provide
flexibility in tortuous anatomy (Fig 1). The delivery system
provides a stepwise gradual deployment that allows very
accurate proximal placement immediately below the most
caudal renal artery (Fig 2). The suprarenal stent remains
constrained with a tip capture mechanism until the desired
position of the proximal fabric is reached, and is then
released gradually with a wheel at the end of the delivery
system. Radio-opaque markers are provided at all levels to
facilitate fluoroscopic imaging and accurate placement. The
main bifurcated components are provided with proximal
diameters ranging from 23 to 36 mm and packed in an 18
Fig 1. The Endurant endograft main body and a contralateral
limb inserted.or 20 French delivery catheter. They are intended to seal in rortic necks measuring 19 to 32mm in diameter. The limbs
ome in 10 to 28 mm diameters for iliac sealing and are
ackaged in a 14 or 16 French carrier. The treatment range
n the iliac arteries is 8 to 25 mm. The single-use delivery
atheter for each component is covered with a hydrophilic
oating to improve delivery in diseased iliac arteries.
The regulatory trial. A multicenter, single arm regu-
atory trial was performed at 26 centers in theUS represent-
ng a mix of academic and private hospitals and multiple
edical specialities (Table A1, online only). Preoperative
omputed tomographic (CT) scans of prospective patients
ere examined by one of five independent expert reviewers
ot participating in the trial prior to enrollment, to ensure
hat anatomic inclusion and exclusion criteria were appro-
riately met. Of particular note among these is the inclu-
ion of neck lengths as short as 10mm. Neck angulations of
0 degrees or less and iliac sealing zones at least 15 mm in
ength were other anatomic requirements. Other criteria
xcluded anatomic high-risk findings such as large throm-
us burden in the sealing zones, and physiological high risk
ndividuals such as American Society of Anesthesiologists
ASA) class IV, similar to most regulatory trials (Complete
riteria in Table A2, online only). Standard implantation
rocedures of the respective institution were used, includ-
ng imaging equipment, choice of anesthesia, and pre- and
ostoperative care. The follow-up schedule included a CT
can and four-view abdominal x-rays at 1, 6, and 12months
ollowing implantation and yearly thereafter. All pre- and
ostoperative imaging was reviewed by an independent
ore laboratory (M2S, West Lebanon, NH), and all adverse
vents except for blood loss were adjudicated by a clinical
vents committee (CEC; Harvard Clinical Research Insti-
ute, Boston, MA). Aneurysm and landing zone diameters
ere obtained from the orthogonal views following 3D
econstructions. A change in AAA diameter of more than 5
m compared with the 1-month baseline measurement
as considered significant. The results presented in this
anuscript are based on the core laboratory and CEC
ssessments for the appropriate endpoint measures and
udited individual site reports for other clinical measures.
ll requested source documents were made available for
irect review by the authors of this report, including all
atients who died and selected patients who experienced
erious adverse events.
The primary safety endpoint for this trial was the inci-
ence of major adverse events (MAE) at 30 days defined as
ll-cause mortality, myocardial infarction, paraplegia,
troke, bowel ischemia, renal or respiratory failure, or blood
oss 1000 mL. The primary effectiveness endpoint was
uccessful aneurysm treatment at 12 months, defined as
echnical success of the original implantation with freedom
rom Type I and III endoleaks, aneurysm rupture, open
onversion to surgery or stent migration anytime through
ne year, and aneurysm enlargement5 mm, or stent graft
cclusion at 12 months. For regulatory purposes, the pri-
ary safety and effectiveness endpoints were compared
ith the already published pivotal trial results of the cur-
ently approved Talent eLPS device (Medtronic Vascular).9
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protocol and consent forms.
Statistical methods. Statistical analysis was only ap-
plied to the comparisons with the Talent eLPS study results
for regulatory purposes. Endpoints were evaluated using
descriptive statistics by study group. A two-sided 95% con-
fidence interval for difference in rates between the Endur-
ant Test Group and Talent eLPS Control Group was con-
structed using the exact method by inverting a single
two-sided test. The Cox regression method was applied to
the late MAE rate to account for subjects who terminated
early from the study. Propensity score analysis based on the
quintile strata was performed to adjust for the potential
biases between the two study groups that could impact
measured outcomes.
RESULTS
Demographics and baseline characteristics. One
hundred fifty patients with a mean age of 73.1  8.0 years
were enrolled in the trial and treated between April 2008
and May 2009 at 26 approved sites. One hundred thirty-
seven patients (91.3%) were males. Baseline patient charac-
teristics as well as associated comorbid conditions are listed
in Table I and are quite typical for this patient population.
Cardiovascular risk factors were present in the majority of
patients. Eighty-two patients (54.7%) were classified as
being Society for Vascular Surgery (SVS) 2 risk category,
and 44 patients (29.3%) were SVS 3 category. Of interest,
29 patients (19.3%) had a family history of AAA. Aneurysm
size averaged 57  8.3 mm (range, 44-97 mm) and prox-
imal neck length 26.5  12.1 mm. A neck length of 10 to
14.9 mm was present in 15 patients (10%).
Procedural data. The implantation procedure was
completed successfully in 149 patients (99.3%). The lone
failure resulted from the inability to access the contralateral
gate that was collapsed in a tight distal aorta. The final
Fig 2. Controlled deployment sequence of the Enduran
above the renal arteries. B, Position adjusted to desired
mechanism of the Endurant. C, Final deployment at inteconfiguration was essentially an aorto-monoiliac recon- dtruction with a fem-fem bypass. One patient experienced a
upture of the neck during ballooning of the main device,
hich had been deployed 5 mm below its target. The
rocedure was completed successfully without any further
omplications by implanting a proximal extension. This was
he lone report of any rupture during the study period.
eneral anesthesia was used in 125 patients (83.3%), and
he average procedure time was 101  46 minutes. Blood
oss averaged 185 168mL, and only one patient received
lood transfusions (0.7%). Hospital stay was 2.1  2.3
ays.
The procedure was completed with a main device and a
ontralateral leg in 105 patients (70%). Forty-two patients
ad iliac extensions; nine on both sides. Three patients had
proximal aortic extension, one in combination with bilat-
ral iliac extensions.
Outcomes at 30 days. There was no mortality at 30
ograft. A, Suprarenal and first sealing stents uncovered
tion with further sheath retraction. Inset, Tip capture
location.
able I. Baseline patient and aneurysm characteristics
ge (years) 73.1  8.0
ender (male) 91.3% (137/150)
aximum abdominal aortic aneurysm
size (mm) 57.0  8.3
roximal neck length (mm) 26.5  12.1
omorbidities
ongestive heart failure 16% (24/150)
ngina 18.0% (27/150)
rrhythmia 39.3% (59/150)
yocardial infarction 30.0% (45/150)
hronic obstructive pulmonary
disease 35.3% (53/150)
ypertension 86.7% (130/150)
bnormal renal function 28.7% (43/150)
eripheral vascular disease 22.7% (34/150)
iabetes 26.7% (40/150)
uantitative measures are expressed in mean  standard deviation while
ualitative measures in percentage of the total population.t end
locaays, and MAE were noted in only six patients (4%), the
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September 2011604 Makaroun et almost frequent being respiratory failure and bowel ischemia
in two patients each (Table II). Serious adverse events
(SAE), whether related to the procedure or not, were
observed in 43 patients (28.7%) through 30 days of follow
up. The most frequently noted category of adverse events
was cardiac, illustrating the high association of AAA with
underlying cardiac disorders. Vascular events were noted in
only 4% of patients. Table III details the reported SAE at 30
days and up to 1 year of follow up. Five reinterventions, all
for arterial events were performed during the first 30 days,
all using open techniques.
One-year outcomes. Six patients expired during the
first year, and one during the second year of follow up.
None were adjudicated to be aneurysm-related (Table IV).
The patient who expired from a stroke at 90 days is one of
the patients who initially had bowel ischemia after the
procedure. All 1-year follow-up visits of surviving patients
were completed. No patient withdrew from the study or
was lost to follow up during the first year. There were no
ruptures, fractures, migrations, or open surgical conver-
sions. An additional five reinterventions were performed
between 30 and 365 days after the index procedure, four
using endovascular techniques.
Endoleaks. No type I or III endoleaks have been
reported through the first year of follow up. Type IV
endoleaks were observed intraoperatively in 18 patients,
but reporting was not uniform and there was no central
review to determine exact incidence. Type II endoleaks
were described in 23 of 143 patients (16.1%) at 1 month,
15 of 129 (11.6%) at 6 months, and 12 of 130 (9.2%) at 1
year. One indeterminate endoleak was also noted at 1 year
(Table V). One of the Type II endoleaks proved ultimately
at angiography to be a distal Type I, due to short coverage
of the left common iliac artery, and was treated with an
extension 14 months after the initial procedure. Though
not associated with any AAA size increase, two Type II
endoleaks were treated by embolization during the first
year.
Sac size change. The baseline AAA diameter was con-
sidered to be the largest orthogonal diameter on the
1-month CT scan and was used for later comparisons of sac
size changes. No patient developed sac enlargement by the
12-month follow-up visit. Sac shrinkage was observed in 64
of 136 (47%) at 1 year, and no significant change was noted
Table II. Thirty-day mortality and morbidity of the
Endurant patients
Thirty-day outcomes
Mortality 0.0% (0/150)
Major adverse event 4.0% (6/150)
Myocardial infarction 0.7% (1/150)
Renal failure 0.7% (1/150)
Respiratory failure 1.3% (2/150)
Stroke 0.7% (1/150)
Bowel ischemia 1.3% (2/150)
Blood loss 1000 mL 0.7% (1/150)in 53% of patients. rReinterventions. Ten reinterventions (6.7%) were
erformed during the first year; four endovascular and six
pen (Table VI). Three early interventions were for vascu-
ar complications closely related to the procedure, and two
nterventions around 8 months later were for Type II
ndoleaks. The other five procedures were for limb stenosis
n one patient treated with a stent, and limb thrombosis in
our. One subacute occlusion was treated by a fem-fem
ypass graft, while the others were treated with stenting
fter thrombectomy in two and lysis in one. Most of the
imb complications were due to external compression in a
mall aorta or kinked iliac arteries. Fig 3 illustrates one of
hese patients. One occlusion was not related to compres-
ion and was due to the stented distal landing zone forming
n acute angle with the redundant tortuous left iliac artery.
Comparison to a control group. For regulatory pur-
oses, the outcomes of the Endurant study were compared
ith the results of the Talent eLPS phase II pivotal trial,
hich have already been reported.9 All baseline AAA char-
cteristics and comorbidities were nearly identical between
he two cohorts, except for more patients in the Talent
tudy with congestive heart failure (28.3% vs 16%; P .01)
nd peripheral vascular disease (46.4% vs 22.7%; P .001),
nd less patients with diabetes (15.7% vs 26.7%; P .019).
ll endpoints as well as all utility measures favored the
ndurant device when compared with the Talent device
xcept for a slightly higher limb occlusion rate in the
ndurant study. The primary safety endpoint, freedom
rom MAE at 30 days, was significantly superior in the
ndurant study (96% vs 89.2%; P  .042). The same was
rue for the primary effectiveness endpoint, successful an-
urysm treatment (97.5% vs 87.1%; P  .027). A Kaplan-
eier depiction of the freedom from adverse events over
he first year for both studies is presented in Fig 4.
ISCUSSION
The perfect endograft remains elusive despite many
ttempts to explore new concepts such as balloon expand-
ble stent grafts, staple fixation to the aortic wall, biopoly-
er filled sealing rings, or space-occupying endobags. The
deal graft would be flexible to treat angulated and tortuous
natomy, yet have enough support to resist external com-
ression. It would be packaged in a low-profile catheter to
avigate small diseased access vessels, but still possess a
turdy and reliable fixation mechanism to the aortic wall to
void migration over time. The delivery mechanism would
rovide gradual, controlled, and accurate deployment to
osition it in the most appropriate sealing zone. In addi-
ion, it must be durable over the long term without late
evice-related failures. The Endurant stent graft system
epresents a new iteration of traditional endografts, with
ome of these characteristics incorporated in its design. It
ombines accurate deployment, active fixation, and flexible
imbs that accommodate tortuous anatomy. It is also deliv-
red in a relatively lower profile system than other current
evices, with a hydrophilic coating that negotiates diseased
nd small iliac arteries well. The outcomes in this pivotal
egulatory trial are excellent and quite encouraging in the
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Volume 54, Number 3 Makaroun et al 605first year after implantation with no aneurysm related mor-
tality, very low MAE rate, and no significant device related
issues. Of course, long-term outcomes are yet to be deter-
mined.
The only complication that occurred with unexpected
frequency in this study was limb compression with resultant
thrombosis in four patients and stenosis in one. Clearly as
stent graft flexibility is increased, the likelihood of limb
compression increases. Implantation methods have to be
modified to account for such behavior, placing additional
emphasis on ballooning with less compliant balloons, lib-
eral use of kissing balloons in tight aortic segments, and if
Table III. Serious adverse events reported during the first
Serious adverse event 0-
Respiratory events 4.0%
Renal events 2.0%
Cardiac events 8.7%
Congestive heart failure 2.0%
Cardiac arrhythmia 2.7%
Myocardial infarction 0.7%
Neurological events 2.7%
Stroke/cerebrovascular accident 0.7%
Gastrointestinal events 4.0%
Bleeding events 3.3%
Vascular events 4.0%
Arterial 3.3%
Arterial insertion trauma 0.0%
Venous 0.0%
Other events 16.0%
Cancer 0.7%
Fever 6.0%
Urologic 4.7%
Wound complication 0.7%
Patients with one or more serious adverse event 28.7%
One patient may have more than one adverse event.
Table IV. Causes of death during follow-up as adjudicate
Primary cause of death Days from implant
Cerebrovascular accident 90
Respiratory arrest 128
Pulmonary fibrosis 215
Lung cancer 267
Multiple organ/system failure 280
Bladder cancer 320
Lung cancer 458
Table V. Endoleaks at various periods of follow up
Endoleaks 1 month
Type I 0.0% (0/143)
Type II 16.1% (23/143)
Type III 0.0% (0/143)
Indeterminate 0.0% (0/143)
Subjects with any endoleak 16.1% (23/143)
The denominator represents the examinations suitable for endoleak determneed be, adding more support in the form of additional etented components. At least three of the four patients with
imb thrombosis might have benefited from such an ap-
roach. In addition, the patient with an acute angle be-
ween the stented limb and the redundant left iliac was
reated successfully with a stent extension, which could
ave easily been performed at the original procedure.
hese cases illustrate the care that must be taken to
nsure a good flow through both limbs in areas of
xternal constriction or iliac tortuosity. Completion an-
iography may not provide the best final assessment to
xclude compression as multiple projections would be
ecessary. Pressure measurements in the femoral sheaths,
of observation
ys 31-365 days 0-365 days
150) 8.7% (13/150) 10.7% (16/150)
150) 2.7% (4/150) 4.7% (7/150)
150) 5.3% (8/150) 12.0% (18/150)
150) 0.0% (0/150) 2.0% (3/150)
150) 1.3% (2/150) 4.0% (6/150)
150) 0.7% (1/150) 1.3% (2/150)
150) 2.0% (3/150) 4.0% (6/150)
150) 2.0% (3/150) 2.0% (3/150)
150) 2.7% (4/150) 6.7% (10/150)
150) 2.7% (4/150) 6.0% (9/150)
150) 2.0% (3/150) 6.0% (9/150)
150) 1.3% (2/150) 4.7% (7/150)
150) 0.0% (0/150) 0.0% (0/150)
150) 0.7% (1/150) 0.7% (1/150)
150) 6.7% (10/150) 22.7% (34/150)
150) 1.3% (2/150) 2.0% (3/150)
150) 0.0% (0/150) 6.0% (9/150)
150) 0.7% (1/150) 5.3% (8/150)
150) 0.0% (0/150) 0.7% (1/150)
150) 25.3% (38/150) 41.3% (62/150)
the clinical events committee
vice-related Procedure-related Aneurysm-related
No No No
No No No
No No No
No No No
No No No
No No No
No No No
6 months 12 months
0.0% (0/129) 0.0% (0/130)
11.6% (15/129) 9.2% (12/130)
0.0% (0/129) 0.0% (0/130)
0.0% (0/129) 0.8% (1/130)
11.6% (15/129) 10.0% (13/130)
.year
30 da
(6/
(3/
(13/
(3/
(4/
(1/
(4/
(1/
(6/
(5/
(6/
(5/
(0/
(0/
(24/
(1/
(9/
(7/
(1/
(43/d by
Despecially after removal of stiff guidewires and carriers
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September 2011606 Makaroun et almay provide valuable physiological confirmation of ade-
quate bilateral flow. The use of intravascular ultrasound
provides another alternative for interrogation of the
limbs, albeit more expensive on a routine basis.
Limb occlusions in the Endurant trial were noted in
four patients (2.7%) during the first year of follow up, a
comparable incidence to the phase II trials of the other five
currently approved devices ranging from 1% to 3%.2,9-12
The highest limb complication rates by far, were with the
Ancure device (Guidant Inc, Menlo Park, Calif), which is
no longer marketed. The Ancure was a flexible unibody
endograft that was entirely unsupported. It suffered from
many limb compression and patency issues, requiring ad-
junctive stenting in 28.1% of patients during the original
procedure and reinterventions in 11.6%.13 Previous stent
graft trials do suggest that the majority of limb complica-
tions occur early and almost never after the first year. This is
again confirmed in the current trial, with all four limb
Table VI. All reinterventions in the Endurant pivotal trial
Time to event (days) Reason for secondary procedur
0 Femoral occlusion
0 Retained stent in femoral artery
1 External iliac dissection
1 Limb graft occlusion
30 Limb graft occlusion
49 Limb graft occlusion
57 Limb graft occlusion
217 Type Ib endoleak found to be Type II on
231 Type II endoleak
304 Limb endograft stenosis
406 Type II endoleak found to be Type Ib on
Ten reinterventions were during the first year.
Fig 3. Right ipsilateral limb occlusion at 20 days treated
a long neck with a plaque at the distal end.A, Preoperative
15.4 mm in diameter. B, The right external iliac is 4 mm
the distal neck (arrow). D, Occluded limb in the aneuryocclusions occurring in the first 2 months. With proper care Eo minimize external compression or having the distal end
f the limbs at a point of significant iliac angulation, this
ncommon and avoidable complication may become quite
are with increasing experience with this device.
Treating AAA patients with adverse neck characteris-
ics, including short infrarenal necks, has been reported to
e successful at least in the short term with many devices in
ost marketing observations.14-16 An increased incidence
f early Type I endoleaks and mid to late term migration is,
owever, an expected risk in these patients. This is less often
ttempted during regulatory trials, although the Talent
tudy did allow very short necks, with the expected associ-
ted endoleaks and migrations.9 The 10 mm threshold for
eck length used in this study appears to be quite safe with
his device, with no migrations or type I endoleaks ob-
erved, at least up to 1 year. Clearly, this period of obser-
ation remains too short to conclude that treatment of such
horter necks is durable. A 2-year experience with the
Procedure performed
Femoral endarterectomy
Retrieval of stent
Patch angioplasty
Thromboembolectomy with stenting
Fem-fem bypass
Thrombolysis with stenting
Thromboembolectomy with stenting
iography Treatment with Cyanobutylacrylate glue
Coil embolization L4 lumbar
Percutaneous transluminal angioplasty with stenting
iography Limb extension
a Fem-Fem bypass graft. The 3D reconstruction reveals
puted tomography (CT) shows the distal neck to be only
he CT at 20 days shows a compressed ipsilateral limb in
c.es
ang
angwith
com
. C, Tndurant, however, at a single center in Germany reports
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Volume 54, Number 3 Makaroun et al 607acceptable findings with even more hostile necks.17 The
good results with short necks appears to be related to the
deliberate and gradual deployment mechanism of the En-
durant, which allows the operator to carefully take advan-
tage of the entire neck length, resulting in good sealing
proximally in all cases. The first stent characteristics appear to
be quite forgiving of anatomic imperfections, adding to the
sealing performance of the endograft. Palmaz stents (Cordis
Johnson & Johnson, Warren, NJ) were nevertheless added in
the proximal sealing zone in three procedures in this study to
achieve a seal. All three were performed by the same investi-
gator, reflecting more a personal choice of technical steps to
deal with a poor seal zone rather than a necessary step for
proximal sealing. This fact also illustrates plainly the wide
variability in EVAR techniques between operators, which
clearly influences reported results, and represents extrapola-
tion from experience with a variety of devices.
A unique characteristic of this regulatory study is the
control arm, which for the first time is actually another
EVAR device. Heretofore, all previous such phase II trials
used open surgery as the gold standard for comparison of
outcomes. This new strategy, approved by the Food and
Drug Administration (FDA) acknowledges two realities
that make using open surgical controls ill-advised. First, the
majority of all suitable AAA patients are currently managed
by EVAR, which makes it de facto the gold standard for
modern management of infrarenal aneurysms. Second,
open surgical intervention has been relegated for years to
more complex patients that, at least anatomically, are not
comparable to the patient population treated by EVAR,
and thus not suited to be an appropriate control arm. In the
current trial, the outcomes of the Endurant test patients
were compared with those in the Talent eLPS study. This
strategy required the use of nearly identical endpoints and
data collection procedures, to permit a proper comparison.
Essentially by all measures, the Endurant results were supe-
Fig 4. Kaplan-Meier estimates of the Freedom from MAE over
the first year of follow up in the Endurant (solid line) and Talent
eLPS (dashed line) groups.rior to the Talent eLPS trial outcomes, probably because ofubstantial improvements in the device and its delivery
ystem. It would be improper, however, to attribute all the
mproved results to the implant, as several years separate the
wo studies, and advances in imaging as well as operator
xperience clearly play an important role in better out-
omes. As an illustration, the low vascular complication
ate, with only one iliac dissection and one femoral artery
hat required repair, is a reflection of improvements in
rofile and surface modifications of new deployment sys-
ems that make EVAR a safer procedure. This should not
etract from the fact that increased awareness by more
xperienced operators, a decade after the commercializa-
ion of EVAR in the US, has also contributed to the low
omplication rate as well as the excellent outcomes re-
orted in this study.
ONCLUSION
The Endurant provides a safe and effective new stent
raft for the treatment of infrarenal aortic aneurysms. The
esults at 1 year are quite encouraging even in patients with
hort proximal AAA necks, with no operative mortality and
low morbidity. Long-term outcomes, however, are still
ending.
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Volume 54, Number 3 Makaroun et al 608.e1Supplementary Table 1 (online only). Investigators and institutions involved in the Endurant Pivotal Study
Investigators Institutions
Michael Tuchek Advocate Good Samaritan Hospital, Downers Grove, Ill
Doug Massop Iowa Methodist Hospital, Des Moines, Iowa
Robert Rhee UPMC, Pittsburgh, Pa
John Henretta Mission Hospital, Asheville, NC
Clifford Buckley Scott and White Memorial Medical Center, Temple, Tex
Manish Mehta Albany Medical Center, Albany, NY
Sharif Ellozy Mount Sinai Medical Center, New York, NY
Mark Fillinger Dartmouth-Hitchcock Medical Center, Lebanon, NH
Ron Fairman University of Pennsylvania Hospital, Philadelphia, Pa
Paul Anain Sisters of Charity Hospital, Buffalo, NY
Matt Eagleton Cleveland Clinic, Cleveland, Ohio
Vito Mantese St John’s Mercy Medical Center, St. Louis, MO
John Runyon Lindner Clinical Trial Center, Cincinnati, Ohio
Tom Maldonado New York University Medical Center, New York, NY
Russell Samson Sarasota Memorial Hospital, Sarasota, Fla
Satish Muluk Allegheny General Hospital, Pittsburgh, Pa
Richard Cambria Massachusetts General Hospital, Boston, Mass
Anthony Comerota Jobst Vascular Center, Toledo, Ohio
William Jordan University of Alabama hospitals, Birmingham, Ala
Edward Diethrich Arizona Heart Institute, Phoenix, Ariz
Patrick Clagett University of Texas Southwestern, Dallas, Tex
Lance Diehl Presbyterian Hospital, Charlotte, NC
Karthik Kasirajan Emory University Hospital, Atlanta, Ga
Mark Eskandari Northwestern University Memorial Hospital, Chicago, Ill
Arun Chervu Wellstar Kennestone Hospital, Marietta, Ga
Jason Lee Stanford University Medical Center, Palo Alto, Calif
Supplementary Table 2 (online only). Inclusion and exclusion criteria for the Endurant pivotal study
Inclusion Criteria
1. Subject is 18 years old.
2. Signed informed consent and is able and willing to comply with the protocol and follow-up.
3. Subject is American Society of Anesthesiologists class I and II, or III.
4. Subject has an abdominal aortic aneurysm that is 5 cm in diameter perpendicular to the line of flow or is 4 to 5 cm in diameter
and has increased 0.5 cm within the last 6 months.
5. Subject meets all the following anatomical criteria
a. The suprarenal angle 45 degrees between the proximal neck and the suprarenal aorta.
b. The infrarenal angulation 60 degrees between the proximal neck and the aneurysm.
c. The infrarenal aneurysmal neck length at least 10 mm in length.
d. The proximal aortic neck diameter 19 mm and 32 mm.
e. The distal fixation of the iliac arteries must have a diameter 8 mm and 25 mm.
f. Adequate access for device delivery
g. Distal fixation length 15 mm bilaterally.
Exclusion criteria
1. Subject has a life expectancy 1 year.
2. Subject is participating in an investigational drug or device study and has not completed the required follow-up at least 1 month
prior to signing the consent form in this study.
3. Subject is a female of childbearing potential in whom pregnancy cannot be excluded.
4. The abdominal aortic aneurysm is suprarenal, isolated ilio-femoral, mycotic, inflammatory, or a pseudoaneurysm.
5. Subject has an untreated thoracic aneurysm 4.5 cm in diameter.
6. Subject requires emergent aneurysm treatment (eg, trauma or rupture).
7. Subject has a history of bleeding diathesis or coagulopathy.
8. Subject had or plans to have an unrelated major surgical or interventional procedure within 1 month before or after implantation
of the Endurant stent graft.
9. Subject had a myocardial infarction or cerebrovascular accident within 3 months prior.
10. Subject has any of the following anatomic criteria
a. Reversed conical neck 4 mm distal increase over a 10 mm length.
b. Significant mural thrombus at either the proximal or distal attachment sites that would compromise fixation and seal of the device
c. Ectatic iliac arteries requiring bilateral exclusion of hypogastric blood flow.
11. Subject has a known allergy or intolerance to the device components.
12. Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, not amenable to pretreatment.
13. Subject is morbidly obese (body mass index 40 kg/m2) or has other documented clinical conditions that severely inhibit
radiographic visualization of the aorta.
14. Subject has active infection at the time of the index procedure.
15. Subject has congenital degenerative collagen disease (eg, Marfan’s syndrome).
16. Subject has a creatinine 2.00 mg/dL (or 182 mol/L) or is on dialysis.
